Ultra-Pure CBD Medicines
Innovative medicines targeting unmet needs, backed by real-world data.
Emyria’s proprietary, ultra-pure cannabinoid treatments have been formulated to address multiple, large unmet needs like psychological distress, irritable bowel syndrome and more - all backed by our unique Real World Data (RWD) model.
EMD-RX5: Low-dose, high bioavailability CBD targeting psychological distress, irritable bowel syndrome and other conditions
More novel dose forms to be announced
Developing innovative treatments for severe psychological conditions
Emyria has exclusive access to a world-class library of over 100 MDMA analogues developed over 10 years by Dr. Matt Piggott at the University of Western Australia.
MDMA analogues have unique biochemical properties that make them attractive small molecules to develop into registered treatments for severe psychological conditions such as Post-Traumatic Stress Disorder.
UWA’s library is therefore a highly valuable drug discovery resource.
20 Mar 2023 - Emyria Expands MDMA Analogue Library to Address Mental Health and Neurological Disorders
Research & Data Programs
Robust and ethically-sourced real-world patient data and technology-driven research programs
Our unique data platform helps us manage, monitor and improve the safety and efficacy of novel treatments for patients with unmet medical needs.
Emyria is also leading numerous innovative grant and award-winning research programs with global partners involving remote monitoring technology and psychedelic-assisted therapy.